Equities researchers at Aegis raised their target price on shares of Trius Therapeutics (NASDAQ: TSRX) from $14.00 to $18.00 in a report issued on Monday. The firm currently has a “buy” rating on the stock.
And more goods news ton come. 2 baggers potential
Sentiment: Strong Buy
might get the GAIN Act status which gives it 5 years of market exclusivity similar to NCE. Higher price for comp. if there is a BO.